Merck & Co., Inc. (NYSE: MRK) has recently received a number of price target changes and ratings updates:
- 11/7/2026 – Merck & Co., Inc. was upgraded by Wall Street Zen from “hold” to “strong-buy”.
- 11/3/2026 – Merck & Co., Inc. is now covered by Argus. They set a “strong-buy” rating on the stock.
- 11/3/2026 – Merck & Co., Inc. was downgraded by DZ Bank from “buy” to “hold”. They now have a $153.00 price target on the stock.
- 11/2/2026 – Merck & Co., Inc. had its price target raised by Freedom Broker from $125.00 to $140.00. They now have a “hold” rating on the stock.
- 11/2/2026 – Merck & Co., Inc. had its price target raised by Cantor Fitzgerald from $145.00 to $155.00. They now have a “neutral” rating on the stock.
- 10/30/2026 – Merck & Co., Inc. had its price target raised by JPMorgan Chase & Co. from $165.00 to $175.00. They now have an “overweight” rating on the stock.
- 10/30/2026 – Merck & Co., Inc. had its price target lowered by Royal Bank Of Canada from $145.00 to $140.00. They now have a “sector perform” rating on the stock.
- 10/30/2026 – Merck & Co., Inc. had its price target raised by Guggenheim from $170.00 to $171.00. They now have a “buy” rating on the stock.
- 10/26/2026 – Merck & Co., Inc. had its price target raised by Barclays from $150.00 to $180.00. They now have an “overweight” rating on the stock.
- 10/19/2026 – Merck & Co., Inc. was downgraded by Zacks Research from “hold” to “strong sell”.
- 10/12/2026 – Merck & Co., Inc. had its price target raised by Citigroup from $125.00 to $145.00. They now have a “neutral” rating on the stock.
- 10/12/2026 – Merck & Co., Inc. had its price target lowered by Royal Bank Of Canada from $150.00 to $145.00. They now have a “sector perform” rating on the stock.
- 10/8/2026 – Merck & Co., Inc. had its price target raised by Cantor Fitzgerald from $120.00 to $145.00. They now have a “neutral” rating on the stock.
- 10/7/2026 – Merck & Co., Inc. had its price target lowered by Morgan Stanley from $179.00 to $177.00. They now have an “overweight” rating on the stock.
- 10/5/2026 – Merck & Co., Inc. had its price target raised by JPMorgan Chase & Co. from $150.00 to $165.00. They now have an “overweight” rating on the stock.
- 10/3/2026 – Merck & Co., Inc. was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/29/2026 – Merck & Co., Inc. had its price target raised by Scotiabank from $155.00 to $180.00. They now have a “sector outperform” rating on the stock.
- 9/23/2026 – Merck & Co., Inc. had its price target raised by TD Cowen from $137.00 to $155.00. They now have a “hold” rating on the stock.
- 9/20/2026 – Merck & Co., Inc. was upgraded by Wall Street Zen from “hold” to “buy”.
Merck & Co., Inc. Trading Down 0.0%
Shares of NYSE MRK opened at $147.74 on Monday. Merck & Co., Inc. has a twelve month low of $91.49 and a twelve month high of $156.92. The firm has a market cap of $364.21 billion, a PE ratio of 152.31, a price-to-earnings-growth ratio of 6.77 and a beta of 0.13. The business has a fifty day simple moving average of $146.16 and a two-hundred day simple moving average of $128.61. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.58 EPS. Analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.
Read More
- Five stocks we like better than Merck & Co., Inc.
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Merck & Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.
